Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

Background Tenofovir disoproxil fumarate (TDF) in combination with other antiretroviral (ARV) drugs has been in clinical use for HIV treatment since its approval in 2001. Although the effectiveness of TDF in preventing perinatal HIV infection is well established, information about renal safety durin...

Full description

Saved in:

Bibliographic Details
Published in:	BMC infectious diseases Vol. 22; no. 1; pp. 1 - 634
Main Authors:	Baltrusaitis, Kristin, Makanani, Bonus, Tierney, Camlin, Fowler, Mary Glenn, Moodley, Dhayendre, Theron, Gerhard, Nyakudya, Lynette H., Tomu, Musunga, Fairlie, Lee, George, Kathleen, Heckman, Barbara, Knowles, Kevin, Browning, Renee, Siberry, George K., Taha, Taha E., Stranix-Chibanda, Lynda, Currier, Judith, Luzuriaga, Katherine, Weinberg, Adriana, McIntyre, James, Chipato, Tsungai, Klingman, Karin, Mpoudi-Ngole, Mireille, Read, Jennifer S., Siberry, George, Watts, Heather, Purdue, Lynette, Fenton, Terrence, Barlow-Mosha, Linda, Toye, Mary Pat, Mirochnick, Mark, Kabat, William B., Chi, Benjamin, Lallemant, Marc, Nielsen, Karin, Butler, Kevin, Angelidou, Konstantia, Shapiro, David, Brummel, Sean, Coletti, Anne, Toone, Veronica, Valentine, Megan, Zadzilka, Amanda, Basar, Michael, Jennings, Amy, Manzella, Adam, Patil, Sandesh, Bhosale, Ramesh, Nevreka, Neetal, Kunje, Salome, Siyasiya, Alex, Maulidi, Mervis, Martinson, Francis, Makina, Ezylia, Milala, Beteniko, Skosana, Nozibusiso Rejoice, Mawlana, Sajeeda, Louw, Jeanne, Rossouw, Magdel, Rossouw, Lindie, Masenya, Masebole, Grab, Janet, Abrahams, Nasreen, Nyati, Mandisa, Dittmer, Sylvia, Chetty, Vani, Desmond, Alicia Catherine, Njau, Boniface, Asiyo, Cynthia, Mlay, Pendo, Owor, Maxensia, Kamateeka, Moreen, Sebikari, Dorothy, Vhembo, Tichaona, Mufukari, Nyasha, Nematadzira, Teacler, Chareka, Gift, Dimairo, Jean, Kusakara, Bangani, Mutambanengwe, Mercy, Marote, Emmie
Format:	Journal Article
Language:	English
Published:	London BioMed Central 20-07-2022 BMC
Subjects:	Alliances Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Babies Birth Breastfeeding & lactation Calcium Calcium phosphates Comparative studies Creatinine Disease prevention Drug dosages Enrollments Hepatitis B HIV HIV/AIDS Human immunodeficiency virus Hypophosphatemia Infants Infections Mathematical analysis Pregnancy Prevention of perinatal HIV transmission Renal function Safety Tenofovir Womens health Zidovudine United Kingdom > UK United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background Tenofovir disoproxil fumarate (TDF) in combination with other antiretroviral (ARV) drugs has been in clinical use for HIV treatment since its approval in 2001. Although the effectiveness of TDF in preventing perinatal HIV infection is well established, information about renal safety during pregnancy is still limited. Trial design The IMPAACT PROMISE study was an open-label, strategy trial that randomized pregnant women to one of three arms: TDF based antiretroviral therapy (ART), zidovudine (ZDV) based ART, and ZDV alone (standard of care at start of enrollment). The P1084s substudy was a nested, comparative study of renal outcomes in women and their infants. Methods PROMISE participants (n = 3543) were assessed for renal dysfunction using calculated creatinine clearance (CrCl) at study entry (> 14 weeks gestation), delivery, and postpartum weeks 6, 26, and 74. Of these women, 479 were enrolled in the P1084s substudy that also assessed maternal calcium and phosphate as well as infant calculated CrCl, calcium, and phosphate at birth. Results Among the 1338 women who could be randomized to TDF, less than 1% had a baseline calculated CrCl below 80 mL/min. The mean (standard deviation) maternal calculated CrCl at delivery in the TDF-ART arm [147.0 mL/min (51.4)] was lower than the ZDV-ART [155.0 mL/min (43.3); primary comparison] and the ZDV Alone [158.5 mL/min (45.0)] arms; the mean differences (95% confidence interval) were − 8.0 mL/min (− 14.5, − 1.5) and − 11.5 mL/min (− 18.0, − 4.9), respectively. The TDF-ART arm had lower mean maternal phosphate at delivery compared with the ZDV-ART [− 0.14 mg/dL (− 0.28, − 0.01)] and the ZDV Alone [− 0.17 mg/dL (− 0.31, − 0.02)] arms, and a greater percentage of maternal hypophosphatemia at delivery (4.23%) compared with the ZDV-ART (1.38%) and the ZDV Alone (1.46%) arms. Maternal calcium was similar between arms. In infants, mean calculated CrCl, calcium, and phosphate at birth were similar between arms (all CIs included 0). Conclusions Although mean maternal calculated CrCl at Delivery was lower in the TDF-ART arm, the difference between arms is unlikely to be clinically significant. During pregnancy, the TDF-ART regimen had no observed safety concerns for maternal or infant renal function. Trial Registration: NCT01061151 on 10/02/2010 for PROMISE (1077BF). NCT01066858 on 10/02/2010 for P1084s.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23
ISSN:	1471-2334 1471-2334
DOI:	10.1186/s12879-022-07608-8